ABSTRACT
Background The acceptance of vaccines among pregnant and breastfeeding women is vital to alleviate the risk of contracting and transmitting coronavirus disease 2019 (COVID-19). Therefore, we aimed to assess the COVID-19 vaccine acceptance among pregnant and breastfeeding/lactating women and the factors associated with the acceptance of the COVID-19 vaccine in Saudi Arabia. Methodology A cross-sectional survey was conducted among pregnant and breastfeeding women living in Saudi Arabia. A 23-item, self-administered questionnaire was used to assess the COVID-19 vaccine acceptance among pregnant or lactating women. Results A total of 160 (53.3%) pregnant women and 140 (46.7%) breastfeeding/lactating mothers participated in the study. When the participants were asked, "Have you been vaccinated or are you planning to take the vaccine during pregnancy or breastfeeding/lactation?" 164 (54.7%) responded with "Yes." When compared with breastfeeding/lactating mothers (54, 38.6%), pregnant women had more concerns about the efficacy and safety of COVID-19 vaccination (77 (48.1%); p = 0.043). The probability of rejecting COVID-19 vaccination was higher among breastfeeding/lactating women with a lower education level than those with a tertiary education level (odds ratio = 3.42, confidence interval = 1.24, 9.45, p = 0.018). Conclusions This study reported high acceptance of COVID-19 vaccination in a sample of breastfeeding/lactating women. Concern about vaccine safety among many pregnant women was the major reason for hesitancy. Factors such as low education, concerns regarding the efficacy and safety of the vaccine, and doctors' (e.g., obstetrician and gynecologist) recommendations for the COVID-19 vaccine were associated with vaccine acceptance.
ABSTRACT
OBJECTIVE: This study was designed to evaluate the extent of inappropriate utilization of intravenous proton-pump inhibitors (IV-PPIs) and its financial burden in a Middle Eastern tertiary care university hospital. METHODS: This was an observational, retrospective, cross-sectional study carried out in King Saud University Medical City, Riyadh, Saudi Arabia. During a study period of 6 consecutive weeks, all hospitalized adult patients (age ≥18) who received IV-PPI selected and mapped with their indications. The patient indications analyzed in comparison with the appropriate indications developed based on the evidence from published literature and guidelines. FINDINGS: A total of 347 patients were identified, with a mean age of 51.5 years, of which 51.9% were male. Of all the patients who received IV-PPIs, 251 (72.3%), 66 (19%), and 30 (8.7%) received for stress ulcer prophylaxis (SUP), peptic ulcer disease (PUD) or gastroesophageal reflux diseases (GERDs), and upper gastrointestinal bleeding, respectively. Overall, only 110 (31.7%) of the 347 patients received IV-PPIs appropriately. The patients with SUP showed the highest percentage of inappropriate use of IV-PPI (80.59%) compared to PUD/GERD (19%). The total cost of inappropriate prescription of IV-PPI was 585,167 Saudi Riyal (SAR) (156,044 USD). CONCLUSION: There is a high tendency of IV-PPI's inappropriate prescription in our hospital setting. This large-scale inappropriate prescription of IV-PPI in the hospital setting not only may lead to increased financial burden but also expose patients to number of undesired effects.
